Kyle Doherty

Retifanlimab plus carboplatin and paclitaxel boosted PFS for certain patients with recurrent or metastatic SCAC.

Merck has discontinued the KEYNOTE-867 and KEYNOTE-630 trials evaluating pembrolizumab in non-small cell lung cancer and cutaneous squamous cell carcinoma.

Minimal residual disease status was linked to progression-free survival in patients with chronic lymphocytic leukemia in the first-line treatment setting and with time-limited therapy.

A research statement was released by ASCO that highlights 4 recommendations to improve access to clinical trials by patients with cancer.

Adding blinatumomab to consolidation chemotherapy provided a significant OS benefit in MRD-negative B-cell precursor acute lymphoblastic leukemia.

The FDA approved the Shield blood test for colorectal screening in adults aged 45 years and older with an average risk for the disease.

The monitoring period after CAR T-cell therapy may be safe if shortened due to the lower incidence of ICANS and CRS 2 weeks after treatment in patients with DLBCL.

Disease-free survival and overall survival improved with celecoxib plus advanced chemotherapy in patients with PIK3CA-mutated stage III colon cancer.

The clinical practice guideline from the American Society for Radiation Oncology focuses on the use of definitive and postoperative radiation therapy in patients with HPV-associated oropharyngeal squamous cell carcinoma.

Improving progression-free survival and confirming results with MRD testing were treatment qualities that patients with CLL reported were more important than other factors.

Compared with combination chemotherapy, ribociclib plus endocrine therapy provided a significant progression-free survival benefit in HR-positive, HER2-negative advanced breast cancer.

Treatment with linvoseltamab provided durable efficacy for patients with relapsed/refractory multiple myeloma.

New or worsening anemia may not reduce the clinical benefit derived from ruxolitinib treatment in patients with myelofibrosis.

Perioperative chemotherapy with FLOT improved overall survival in patients with resectable esophageal cancer compared with neoadjuvant chemoradiation with CROSS.

Asciminib led to a superior 48-week major molecular response rate compared with investigator-selected tyrosine kinase inhibitors for Ph-positive chronic phase chronic myeloid leukemia.

Community urology practices have routinely used darolutamide in both doublet and triplet regimens to treat metastatic hormone-sensitive prostate cancer.

A multipeptide vaccine combination approach may extend survival in stage IIB to IV melanoma.

Enzalutamide with and without leuprolide improves rates of undetectable PSA levels compared with leuprolide alone in castration-sensitive prostate cancer.

The duration of neoadjuvant chemotherapy may be optimized via MRI guidance for the treatment of hormone receptor-negative/HER2-positive breast cancer.

Patients with Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive bladder cancer treated with TAR-200 exhibited a high complete response rate to the treatment.

Patients with newly diagnosed and recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer treated with UGN-102 displayed meaningful and similar responses and disease-free survival regardless of whether they underwent surgery.

Breast-conserving therapy following preoperative systemic therapy resulted in superior overall survival compared with mastectomy in patients with HER2-positive breast cancer.

Genetic testing decisions in patients with cancer may be affected by significant out-of-pocket costs.

As part of a survey of practicing oncologists in the United States, clinicians may have ethical concerns around using artificial intelligence in cancer care.

Patients with early-stage breast cancer treated with ribociclib plus a nonsteroidal aromatase inhibitor provided a greater invasive disease-free survival benefit compared with nonsteroidal aromatase inhibitor therapy alone.

Progression-free and overall survival benefits were obtained with MRD-guided ibrutinib plus venetoclax when compared with fludarabine plus cyclophosphamide and rituximab in chronic lymphocytic leukemia.

Venetoclax provided long-lasting responses in patients with relapsed/refractory chronic lymphocytic leukemia.

A next-generation stool DNA test had higher sensitivity for CRC and advanced precancerous lesions but lower specificity for advanced neoplasia compared with a fecal immunochemical test.

Disease-free survival rates were extended in patients with upper tract urothelial cancer treated with adjuvant chemotherapy after nephroureterectomy compared with those who underwent surveillance.

A biologics license application has been accepted by the FDA for first-line tislelizumab plus chemotherapy for gastric/gastroesophageal junction cancer.